IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders
IRLAB announced today that a publication based on the results of the clinical phase IIa study with IRL752 in patients with Parkinson’s disease is accepted and now published in the scientific journal Movement Disorders."External validation of our research and drug development is important. Publication of clinical study results in such a highly ranked journal as Movement Disorders is central in the development of IRL752 and considered a milestone for the company. The aim with IRL752 is to improve balance and reduce the risk of falls in patients with Parkinson’s disease, which is the current